Emergence and Growth of the Treatment for Syndromes of Dementia and Movement Disorders Market


  • Published On : Dec 22, 2014
Dementia refers to a state wherein there is a severe decline in mental abilities – whether memory, perception, communication, or reasoning – which interferes with a person’s ability to perform daily activities. The treatment for syndromes of dementia and movement disorders market has received a tremendous boost over the years owing to various demographic and technological factors.

The rise in global geriatric population has led to a subsequent increase in the prevalence of neurodegenerative disorders, thereby fueling the treatment for syndromes of dementia and movement disorders market. Moreover, there has also been a stark rise in awareness regarding mental diseases as well as in R&D investments in terms of drug discovery and developments. This has further resulted in the growth of the treatment for syndromes of dementia and movement disorders market on a global scale. The increasing number of partnerships and collaborations among companies dealing with the treatment for syndromes of dementia and movement disorders is expected to greatly impact the market.

In contrast, the inadequacy of comprehensive therapeutic management of movement disorders and dementia, lengthy drug approval period, and strict regulatory prerequisites are anticipated to hamper the growth of the treatment for syndromes of dementia and movement disorders market.

Treatment for syndromes of dementia and movement disorders market: Segmentation and scope 

The treatment for syndromes of dementia and movement disorders market can be segmented on the basis of various criteria. By drugs used for the treatment of progressive dementia, the market for treatment for syndromes of dementia and movement disorders is bifurcated into drugs for progressive dementia and diseases-based therapeutics under progressive dementia. On the basis of drugs used for the treatment of progressive dementia with other neurological abnormalities, the worldwide treatment for syndromes of dementia and movement disorders market is divided into drugs for progressive dementia and diseases-based therapeutics under progressive dementia with other neurological abnormalities. By drugs used to treat movement disorder syndrome, the market can be segmented into drugs for movement disorder syndrome and diseases-based therapeutics under movement disorder syndrome. Region-wise, the global treatment for syndromes of dementia and movement disorders market is divided into three main regions: North America, Europe, and Asia.

Over and above these, the treatment for syndromes of dementia and movement disorders market can also be broadly categorized into technological treatment and neurodegenerative disease-based drug treatment. The various technologies used for the treatment for syndromes of dementia and movement disorders include monoclonal antibodies, biomarkers, tau tangling inhibitors, and immunization strategy. Neurodegenerative diseases include Huntington’s disease, Lewy body dementia, Parkinson’s disease, Alzheimer’s disease, frontotemporal dementia, and Pick’s disease.

Global outlook

The worldwide market for treatment for syndromes of dementia and movement disorders stood at US$12,859.8 million in 2014 and – advancing at an 8.6% CAGR during the forecast period – is projected to be worth US$21,154.8 million by 2020. 

The Alzheimer’s disease segment of the treatment for syndromes of dementia and movement disorders market was estimated to be worth US$4,755.2 million in 2014 and is projected to be worth US$8,208.2 million by 2020 at a CAGR of 9.5% from 2014-2020.

Geographically, North America leads the global treatment for syndromes of dementia and movement disorders market owing to expanding geriatric population, growing incidences of neurodegenerative diseases, and lack of appropriate medication for the treatment for syndromes of dementia and movement disorders. The European treatment for syndromes of dementia and movement disorders market is also strong and is driven by factors such as increasing aging population and growing prevalence of mental disorders. Public as well as private healthcare institutes have been working towards creating awareness regarding the control of neurodegenerative disorders, thereby fueling the growth of the treatment for syndromes of dementia and movement disorders market in this region. Asia-Pacific, on the other hand, is expected to witness considerably higher growth during the forecast period due to larger population base and increasing penetration of health insurance.

The prominent players of the global treatment for syndromes of dementia and movement disorders market include AstraZeneca GmbH, Abbott Laboratories, Inc., F. Hoffmann-La Roche, Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, Baxter, Valeant Pharmaceuticals International, Inc., Novartis AG, Pfizer, Inc., and Sanofi.

Browse Full Treatment for Syndromes of Dementia and Movement Disorders Market Research Report With Complete TOC @ http://www.persistencemarketresearch.com/market-research/treatment-syndromes-dementia-movement-disorders-market.asp
Back To Top